Drugs / Allogenic NK cells
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 01 trial | ||||||
| Phase 0 | NCT05744440 | Mar 2023 → May 2025 | acute myeloid leukemia | Xuzhou Medical University | Unknown | No outcome recorded |
| Phase 1/21 trial | ||||||
| Phase 1/2 | NCT01947322 | May 2011 → Jan 2016 | acute myeloid leukemia | Assistance Publique - Hôpitaux de Paris | Completed | No outcome recorded |
| Comparator or background therapy1 trial | ||||||
| Phase 1 | NCT06674265 Comparator | Nov 2024 → Nov 2026 expected | neuroblastoma | Marzieh Ebrahimi | Recruiting | No outcome recorded |
Evidence & citations 5 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Allogenic NK cells | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06674265 ↗ |
| Known as | Natural Killer (NK) cells | “Natural Killer (NK) cells are extracted from a healthy donor through apheresis” NCT06674265 ↗ |
| Action | Deplete | “Target cells will be killed in the absence of interaction between NK inhibitory receptors and their ligands” NCT01947322 ↗ |
| Modality | Cell therapy | “adoptive anti-leukaemic immunotherapy by infusion of HLA-I mismatched NK cells” NCT01947322 ↗ |
| Route | Other | “allogenic NK cells infusion” NCT05744440 ↗ |